ArticleNature communications2025
Breaking barriers in crosslinking mass spectrometry with enhanced throughput and sensitivity using Orbitrap Astral.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Unified down-stream analysis of crosslinking mass spectrometry results with pyXLMS.Nature communications · 2026Article
- Mass Spectrometric Detected Cancer Proteins as Resources for Cancer Research.Journal of proteome research · 2026Article
- What Are the Practical Applications of Single-Cell Proteomics?Proteomes · 2026Article
- Evaluation of a Prototype Orbitrap Astral Zoom Mass Spectrometer for Quantitative Proteomics─Beyond Identification Lists.Journal of proteome research · 2025Article
- Evaluation of a prototype Orbitrap Astral Zoom mass spectrometer for quantitative proteomics - Beyond identification lists.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Crosslinking mass spectrometry is an essential tool for probing protein-protein interactions and structural organization. We here compare Orbitrap Astral and Orbitrap Eclipse instruments using Cas9 crosslinked with PhoX and DSSO under standardized chromatographic and acquisition conditions. The Astral identifies over 40% more unique residue pairs, largely due to increased MS1 sensitivity and efficient detection of low-abundance precursors. Implementation of high-field asymmetric ion mobility spectrometry further increases identifications by 30% through improved precursor filtering. On the Astral, single higher-energy collisional dissociation consistently outperforms stepped fragmentation, particularly at low sample amounts, whereas the Eclipse shows minimal dependence on fragmentation strategy. Gradient optimization experiments demonstrate that longer separations enhance identifications in purified crosslinked samples, while gains plateau in complex backgrounds, indicating the need for enrichment or isolation strategies. Column comparisons show that pore size and particle diameter affect separation efficiency, with the Aurora Ultimate column yielding sharper peaks and more crosslink identifications than PepMap. Together, these findings emphasize that instrument choice, fragmentation mode, and chromatographic design directly influence crosslinking performance. The Astral's combination of sensitivity and scan speed supports comprehensive detection of low-abundance crosslinks, providing deeper structural coverage of protein interaction networks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.